Direct Oral Anticoagulants versus Vitamin K Antagonists for Left Ventricular Thrombus: A Meta-Analysis with Trial Sequential Analysis Anticoagulantes Orais Diretos versus Antagonistas da Vitamina K para Trombo Ventricular Esquerdo: Uma Metanálise com Análise Sequencial de Ensaios
Tipo
Artigo
Data de publicação
2024
Periódico
Arquivos Brasileiros de Cardiologia
Citações (Scopus)
0
Autores
Pasqualotto E.
Gewehr D.M.
Ferreira R.O.M.
Chavez M.P.
Silva C.H.
Cruz S.A.
Limachi-Choque J.
Park A.
de Azeredo Coutinho M.S.S.
Kubrusly L.F.
Gewehr D.M.
Ferreira R.O.M.
Chavez M.P.
Silva C.H.
Cruz S.A.
Limachi-Choque J.
Park A.
de Azeredo Coutinho M.S.S.
Kubrusly L.F.
Orientador
Título da Revista
ISSN da Revista
Título de Volume
Membros da banca
Programa
Resumo
© 2024, Sociedade Brasileira de Cardiologia. All rights reserved.Background: Vitamin K antagonists (VKAs) are the recommended first-line treatment for left ventricular thrombus (LVT); however, direct oral anticoagulants (DOACs) have been considered an alternative therapy. Objectives: To evaluate the efficacy and safety of DOACs compared with VKAs therapy in patients with LVT. Methods: PubMed, Embase, and Cochrane were systematically searched for randomized clinical trials or cohort studies that compared DOACs versus VKAs for LVT. Risk ratios (RRs) were computed for binary endpoints, with 95% confidence intervals (95% CIs). Statistical significance was defined as p value < 0.05. Results: A total of 4 randomized clinical trials and 29 cohort studies were included, with 4,450 patients assigned to either DOACs or VKAs. There was no significant difference between groups for stroke or systemic embolic (SSE) events (RR 0.84; 95% CI 0.65 to 1.07; p = 0.157), stroke (RR 0.73; 95% CI 0.48 to 1.11; p = 0.140), systemic embolic (SE) events (RR 0.69; 95% CI 0.40 to 1.17; p = 0.166), thrombus resolution (RR 1.05; 95% CI 0.99 to 1.11; p = 0.077), any bleeding (RR 0.78; 95% CI 0.60 to 1.00; p = 0.054), clinically relevant bleeding (RR 0.69; 95% CI 0.46 to 1.03; p = 0.066), minor bleeding (RR 0.73; 95% CI 0.43 to 1.23; p = 0.234), major bleeding (RR 0.87; 95% CI 0.42 to 1.80; p = 0.705), and all-cause mortality (RR 1.05; 95% CI 0.79 to 1.39; p = 0.752). Compared with VKAs, rivaroxaban significantly reduced SSE events (RR 0.35; 95% CI 0.16 to 0.91; p = 0.029) and SE events (RR 0.39; 95% CI 0.16 to 0.95; p = 0.037). Conclusions: DOACs had a similar rate of thromboembolic and hemorrhagic events, as well as thrombus resolution, compared to VKAs in the treatment of LVTs. Rivaroxaban therapy had a significant reduction in thromboembolic events, compared to VKAs.
Descrição
Palavras-chave
Assuntos Scopus
Administration, Oral , Anticoagulants , Heart Diseases , Heart Ventricles , Hemorrhage , Humans , Randomized Controlled Trials as Topic , Stroke , Thrombosis , Treatment Outcome , Vitamin K